Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 1, 2026, 11:22 AM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1345–1368 of 1,471 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Safety Testing Clear all
Terminated Phase 2 Interventional Results available

A Study to Test Whether BI 706321 Combined With Ustekinumab Helps People With Crohn's Disease

NCT04978493
View directory record Official record
Conditions
Crohn Disease
Interventions
BI 706321, Ustekinumab, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 75 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
15
States / cities
Northridge, California • Hialeah, Florida • Inverness, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2025 · Synced Nov 1, 2026, 11:22 AM EST
Completed Not applicable Interventional

A Comprehensive Approach to Secondary HIV Prevention and Care Among Positives

NCT01935440
View directory record Official record
Conditions
HIV
Interventions
Prevention & Testing, Prevention & Testing Control
Behavioral
Lead sponsor
Johns Hopkins Bloomberg School of Public Health
Other
Eligibility
18 Years and older
Enrollment
632 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 9, 2018 · Synced Nov 1, 2026, 11:22 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate the Safety and Pharmacokinetics of a Single Dose of GSK2256294 in Healthy Young Males and Elderly Subjects

NCT02006537
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
GSK2256294
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 9, 2017 · Synced Nov 1, 2026, 11:22 AM EST
Active, not recruiting Phase 1 Interventional

Study Evaluating Safety and Efficacy of UCART123v1.2 in Patients With Relapsed/Refractory Acute Myeloid Leukemia

NCT03190278
View directory record Official record
Conditions
Relapsed/Refractory Acute Myeloid Leukemia
Interventions
UCART123v1.2
Biological
Lead sponsor
Cellectis S.A.
Industry
Eligibility
18 Years to 65 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
8
States / cities
San Francisco, California • Tampa, Florida • Chicago, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2025 · Synced Nov 1, 2026, 11:22 AM EST
Completed Phase 4 Interventional

The Long-Term Quitting (Smoking Cessation) Study

NCT02564315
View directory record Official record
Conditions
Smoking Cessation
Interventions
Nicotine Mini-Lozenge for 11 Months, Preparation Phase Behavioral Reduction Counseling, Preparation Phase Recycling Counseling, Preparation Phase Control Treatment, Cessation Phase Supportive Counseling, Cessation Phase Skill Training Counseling, Cessation Phase Brief Information, Cessation Phase Nicotine Patch + Nicotine Mini-Lozenge
Drug · Behavioral
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
1,154 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Feb 17, 2020 · Synced Nov 1, 2026, 11:22 AM EST
Completed Phase 2 Interventional Results available

Study to Test GSK256073 in Patients With Dyslipidemia

NCT00903617
View directory record Official record
Conditions
Dyslipidaemias, Dyslipidemias
Interventions
GSK256073, Placebo, Niaspan
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 75 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
11
States / cities
Pembroke Pines, Florida • Indianapolis, Indiana • Louisville, Kentucky + 8 more
Source: ClinicalTrials.gov public record
Updated Dec 5, 2019 · Synced Nov 1, 2026, 11:22 AM EST
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Study to Test the Efficacy of Online Education to Increase Safe Use of Opioid Medication.

NCT01770314
View directory record Official record
Conditions
Medication Adherence
Interventions
Experimental
Behavioral
Lead sponsor
Inflexxion, Inc.
Industry
Eligibility
18 Years and older
Enrollment
176 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Newton, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 19, 2014 · Synced Nov 1, 2026, 11:22 AM EST
Completed Phase 2Phase 3 Interventional Results available

Study of Rogaratinib (BAY1163877) vs Chemotherapy in Patients With FGFR (Fibroblast Growth Factor Receptor)-Positive Locally Advanced or Metastatic Urothelial Carcinoma

NCT03410693
View directory record Official record
Conditions
Carcinoma, Transitional Cell
Interventions
Rogaratinib (BAY1163877), Chemotherapy
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
16
States / cities
Anchorage, Alaska • Tucson, Arizona • Los Angeles, California + 13 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2022 · Synced Nov 1, 2026, 11:22 AM EST
Active, not recruiting Phase 3 Interventional

Study to Evaluate the Efficacy, Safety and Tolerability of IMU-838 in Patients With Relapsing Multiple Sclerosis

NCT05201638
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
IMU-838 tablets, Placebo matching IMU-838 tablets
Drug
Lead sponsor
Immunic AG
Industry
Eligibility
18 Years to 55 Years
Enrollment
1,100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2033
U.S. locations
2
States / cities
Altamonte Springs, Florida • Coral Springs, Florida
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Nov 1, 2026, 11:22 AM EST
Recruiting Not applicable Interventional

SABER Study for Selected Early Stage Breast Cancer

NCT04360330
View directory record Official record
Conditions
Breast Cancer, Early-stage Breast Cancer
Interventions
Stereotactic Ablative Breast Radiotherapy
Radiation
Lead sponsor
University of Miami
Other
Eligibility
50 Years and older · Female only
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2029
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Nov 1, 2026, 11:22 AM EST
Completed Early Phase 1 Interventional Results available

Mitomycin C With Hyperthermia and Intravesical Mitomycin C to Treat Recurrent Bladder Cancer

NCT00734994
View directory record Official record
Conditions
Transitional Cell Carcinoma of Bladder, Superficial Bladder Cancer
Interventions
Hyperthermia System, Mitomycin C
Device · Drug
Lead sponsor
Mark Dewhirst
Other
Eligibility
18 Years to 75 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 29, 2015 · Synced Nov 1, 2026, 11:22 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Safety, Tolerability, and Pharmacokinetics of Oral EC5026 in Healthy Subjects

NCT04228302
View directory record Official record
Conditions
Healthy Adults
Interventions
EC5026 oral capsule, Placebo oral capsule
Drug · Other
Lead sponsor
EicOsis Human Health Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jul 1, 2021 · Synced Nov 1, 2026, 11:22 AM EST
Completed Not applicable Interventional Results available

Feasibility of Remote Tai Chi

NCT05693805
View directory record Official record
Conditions
PTSD, Pain, Chronic
Interventions
Tai Chi, Wellness program
Behavioral
Lead sponsor
Boston University
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 20, 2026 · Synced Nov 1, 2026, 11:22 AM EST
Completed Phase 1 Interventional

A Dose-regimen Finding Study to Evaluate Safety, Tolerability, Pharmacokinetics and Activity of Oratecan in Subjects With Advanced Malignancies

NCT02250157
View directory record Official record
Conditions
Solid Tumor
Interventions
Oratecan
Drug
Lead sponsor
Athenex, Inc.
Industry
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
2
States / cities
Aurora, Colorado • Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Feb 22, 2022 · Synced Nov 1, 2026, 11:22 AM EST
Completed Phase 2 Interventional Results available

Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution Once Daily and Twice Daily in Subjects With Primary Open-Angle Glaucoma SPECTRUM 6

NCT03858894
View directory record Official record
Conditions
Primary Open-angle Glaucoma and Ocular Hypertension
Interventions
DE-117 Ophthalmic Solution QD, DE-117 Ophthalmic Solution BID
Drug
Lead sponsor
Santen Inc.
Industry
Eligibility
18 Years and older
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
13
States / cities
Los Angeles, California • Danbury, Connecticut • Brooksville, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Aug 4, 2020 · Synced Nov 1, 2026, 11:22 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers

Bioequivalence of TTYP01 Tablets in Healthy Adult Subjects

NCT06107205
View directory record Official record
Conditions
Healthy Adult Subjects
Interventions
TTYP01, Radicava, Radicava ORS
Drug
Lead sponsor
Shanghai Auzone Biological Technology Co., Ltd.
Industry
Eligibility
20 Years to 45 Years
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Apr 24, 2026 · Synced Nov 1, 2026, 11:22 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase I Study of AG-348 in Healthy Volunteers

NCT02149966
View directory record Official record
Conditions
Healthy Volunteer
Interventions
AG-348, Placebo
Drug
Lead sponsor
Agios Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 10, 2014 · Synced Nov 1, 2026, 11:22 AM EST
Active, not recruiting Phase 1Phase 2 Interventional

Safety, Tolerability, and Efficacy of Immunomodulation With A Monoclonal Antibody Against CD40L in Combination With Transplanted Islet Cells in Adults With Brittle Type 1 Diabetes Mellitus (T1D)

NCT06305286
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Islet transplantation with Tegoprubart (AT-1501) immunosupression-based therapy
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 65 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Nov 1, 2026, 11:22 AM EST
Completed Not applicable Interventional

Neurotech Vital Compact Versus Itouch Sure Pelvic Floor Exerciser US

NCT02423005
View directory record Official record
Conditions
Stress Urinary Incontinence
Interventions
Neurotech Vital Compact, itouch Sure Pelvic Floor Exerciser
Device
Lead sponsor
Atlantic Therapeutics
Other
Eligibility
18 Years to 65 Years · Female only
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
12
States / cities
Phoenix, Arizona • Orange, California • Hartford, Connecticut + 9 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2018 · Synced Nov 1, 2026, 11:22 AM EST
Completed Phase 1 Interventional

This Study Tests a New Medicine Called BI 685509 in Patients That Have Kidney Problems Because of Diabetes. The Study Tests How BI 685509 is Taken up in the Body and How Well it is Tolerated (Multiple Rising Doses)

NCT03165227
View directory record Official record
Conditions
Diabetic Nephropathies
Interventions
BI 685509, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
22
States / cities
Huntsville, Alabama • La Mesa, California • Los Gatos, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2020 · Synced Nov 1, 2026, 11:22 AM EST
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Cerebello-Cortical Connectivity and Balance Adaptation in Younger and Older Adults

NCT07901322
View directory record Official record
Conditions
Aging, Postural Balance, Motor Adaptation
Interventions
Transcranial Magnetic Stimulation Assessment, Reactive Balance Adaptation Task
Device · Behavioral
Lead sponsor
University of Minnesota
Other
Eligibility
21 Years to 95 Years
Enrollment
58 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2027 – 2028
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 28, 2026 · Synced Nov 1, 2026, 11:22 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers

Study To Evaluate Safety And Tolerability Of Single And Multiple Ascending Doses Of PF- 06260414 In Healthy Western And Japanese Male Subjects

NCT02070939
View directory record Official record
Conditions
Healthy
Interventions
PF-06260414, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
21 Years to 50 Years · Male only
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Nov 14, 2018 · Synced Nov 1, 2026, 11:22 AM EST
Recruiting Phase 1 Interventional Accepts healthy volunteers

Safety and Tolerability Study of VVZ-2471 in Healthy Volunteers

NCT07531316
View directory record Official record
Conditions
Healthy Controls
Interventions
Placebo pills for 14-day intervention, VVZ-2471 for 14-day intervention
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2031
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Nov 1, 2026, 11:22 AM EST
Enrolling by invitation Not applicable Interventional Accepts healthy volunteers

TESTING AN MTM THEORY-BASED INTERVENTION ON REDUCING DROWSY DRIVING BEHAVIOR, "STAY AWAKE, STAY ALIVE ©," AMONG COLLEGE STUDENTS

NCT07434921
View directory record Official record
Conditions
Drowsiness, Sleep Deprivation, Fatigue
Interventions
MTM Theory based intervention, Standard AAA Knowledge based
Behavioral
Lead sponsor
University of Nevada, Las Vegas
Other
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated May 26, 2026 · Synced Nov 1, 2026, 11:22 AM EST